Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 21;138(16):1465–1480. doi: 10.1182/blood.2020009871

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 7. — High frequency of cytokine-producing NK cells predicts increased severity and poor prognosis for ALL. (A) Comparison of transcript levels of GM-CSF (CSF2), TNF-β (LTA), TNF-C (LTB), and IFN-γ between COG P9906 B-ALL patients (GSE11877), assigned to 2 groups using CIBERSORT, as 100% resting NK cells (n = 73) or 100% activated NK cells (n = 85). Data are shown as median ± interquartile range. (B) CIBERSORT was used to compare the estimated relative proportions of resting and activated NK cells within total NK cells in GM-CSF^HighTNF^HighIFN-γ^High (n = 22) and GM-CSF^LowTNF^LowIFN-γ^Low (n = 19) B-ALL patients from COG P9906 (GSE11877). Patients were assigned to high and low groups based on the median expression of each transcript. The LM22 signature matrix (GSE22886), which contains the transcriptomic profile of resting NK cells and cytokine (IL-2, IL-15)–activated NK cells, was used to deconvolute the bulk transcriptomic profiles of COG P9906 B-ALL patients. Data are median ± interquartile range. (C) Stacked bar charts comparing the proportions of GM-CSF^HighTNF^HighIFN-γ^High and GM-CSF^LowTNF^LowIFN-γ^Low COG P9906 B-ALL patients (GSE11877) with WBC count >100 000, relapse, CNS involvement (CNS⁺), testicular involvement in male patients (Testicular⁺), and positive MRD on day 29 (MRD⁺). (D) Comparison of RFS probabilities of GM-CSF^HighTNF^HighIFN-γ^High and GM-CSF^LowTNF^LowIFN-γ^Low COG P9906 patients with B-ALL (GSE11877). (E) Comparison of overall survival probabilities of CyTOF patients with B/T-ALL (n = 20) divided into 2 groups based on the median frequencies of GM-CSF⁺, TNF⁺, and IFN-γ⁺ NK cells as High GM-CSF⁺TNF⁺IFN-γ⁺ NK cells and Low GM-CSF⁺TNF⁺IFN-γ⁺ NK cells. Stacked bar charts comparing the proportions of High GM-CSF⁺TNF⁺IFN-γ⁺ NK cells and Low GM-CSF⁺TNF⁺IFN-γ⁺NK cells using CyTOF in B/T-ALL patients based on WBC count (F) and survival (G). Survival curves were produced using the Kaplan-Meier method. For survival curves, exact P values were calculated using the log-rank test. For all other analyses, the exact P values were calculated using the Mann-Whitney U test, HR, hazard ratio.